Aberdeen Group
ELOX

Aberdeen Group’s Eloxx Pharmaceuticals ELOX Stock Holding History

Aberdeen Group’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.55M Buy
+400,000
New +$5.1M 0.01% 683

Other funds holding ELOX

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $194M AUM
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return
OPTFSNA
Old Point Trust & Financial Services N A Newport News, Virginia $329M AUM 22.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Aberdeen Group's ELOX Position: Q2 2026 in Review

Aberdeen Group opened a new position in Eloxx Pharmaceuticals (ELOX) in Q2 2026: 400,000 shares worth $5.55M. The stake represents 0.01% of the portfolio and ranks #683 among its holdings.

14 funds tracked by Wall St. Rank hold ELOX as of Q2 2026.

  • Aberdeen Group held 400,000 shares of Eloxx Pharmaceuticals worth $5.55M as of Q2 2026.
  • Eloxx Pharmaceuticals was a new Aberdeen Group position in Q2 2026.
  • Eloxx Pharmaceuticals made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #683 holding.
  • 14 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.